A synonymous polymorphism of the Tristetraprolin (TTP) gene, an AU-rich mRNA-binding protein, affects translation efficiency and response to Herceptin treatment in breast cancer patients

Eberhardt, 2007, Modulation of mRNA stability as a novel therapeutic approach, Pharmacol. Ther., 114, 56, 10.1016/j.pharmthera.2007.01.002

Carrick, 2004, The tandem CCCH zinc finger protein tristetraprolin and its relevance to cytokine mRNA turnover and arthritis, Arthritis Res. Ther., 6, 248, 10.1186/ar1441

Cao, 2004, Immunological characterization of tristetraprolin as a low abundance, inducible, stable cytosolic protein, J. Biol. Chem., 279, 21489, 10.1074/jbc.M400900200

Brook, 2006, Posttranslational regulation of tristetraprolin subcellular localization and protein stability by p38 mitogen-activated protein kinase and extracellular signal-regulated kinase pathways, Mol. Cell. Biol., 26, 2408, 10.1128/MCB.26.6.2408-2418.2006

Essafi-Benkhadir, 2007, Tristetraprolin inhibits Ras-dependent tumor vascularization by inducing vascular endothelial growth factor mRNA degradation, Mol. Biol. Cell, 18, 4648, 10.1091/mbc.E07-06-0570

Sandler, 2008, Control of mRNA decay by phosphorylation of tristetraprolin, Biochem. Soc. Trans., 36, 491, 10.1042/BST0360491

Taylor, 1996, A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency, Immunity, 4, 445, 10.1016/S1074-7613(00)80411-2

Carballo, 1997, Bone marrow transplantation reproduces the tristetraprolin-deficiency syndrome in recombination activating gene-2 (−/−) mice. Evidence that monocyte/macrophage progenitors may be responsible for TNFalpha overproduction, J. Clin. Invest., 100, 986, 10.1172/JCI119649

Carballo, 2000, Evidence that tristetraprolin is a physiological regulator of granulocyte-macrophage colony-stimulating factor messenger RNA deadenylation and stability, Blood, 95, 1891, 10.1182/blood.V95.6.1891

Sawaoka, 2003, Tristetraprolin binds to the 3′-untranslated region of cyclooxygenase-2 mRNA. A polyadenylation variant in a cancer cell line lacks the binding site, J. Biol. Chem., 278, 13928, 10.1074/jbc.M300016200

Datta, 2008, Tristetraprolin regulates CXCL1 (KC) mRNA stability, J. Immunol., 180, 2545, 10.4049/jimmunol.180.4.2545

Suswam, 2008, Tristetraprolin down-regulates interleukin-8 and vascular endothelial growth factor in malignant glioma cells, Cancer Res., 68, 674, 10.1158/0008-5472.CAN-07-2751

Kim, 2010, Tristetraprolin regulates the stability of HIF-1alpha mRNA during prolonged hypoxia, Biochem. Biophys. Res. Commun., 391, 963, 10.1016/j.bbrc.2009.11.174

Brennan, 2009, The mRNA-destabilizing protein tristetraprolin is suppressed in many cancers, altering tumorigenic phenotypes and patient prognosis, Cancer Res., 69, 5168, 10.1158/0008-5472.CAN-08-4238

Al-Souhibani, 2010, The RNA-binding zinc-finger protein tristetraprolin regulates AU-rich mRNAs involved in breast cancer-related processes, Oncogene, 29, 4205, 10.1038/onc.2010.168

Lee, 2010, Tristetraprolin regulates expression of VEGF and tumorigenesis in human colon cancer, Int. J. Cancer, 126, 1817, 10.1002/ijc.24847

Kamangar, 2006, Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world, J. Clin. Oncol., 24, 2137, 10.1200/JCO.2005.05.2308

Mahtani, 2001, Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability, Mol. Cell. Biol., 21, 6461, 10.1128/MCB.21.9.6461-6469.2001

Bourcier, 2011, Constitutive ERK activity induces down-regulation of Tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells, Am. J. Physiol. Cell Physiol., 301, 609, 10.1152/ajpcell.00506.2010

Lai, 1999, Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA, Mol. Cell. Biol., 19, 4311, 10.1128/MCB.19.6.4311

Hall, 2009, Current perspective - trastuzumab, Eur. J. Cancer., 45, 12, 10.1016/j.ejca.2008.10.013

Sauna, 2007, Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer, Cancer Res., 67, 9609, 10.1158/0008-5472.CAN-07-2377

Marderosian, 2006, Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling, Oncogene, 25, 6277, 10.1038/sj.onc.1209645

Lee, 2010, Stability of the LATS2 tumor suppressor gene is regulated by tristetraprolin, J. Biol. Chem., 285, 17329, 10.1074/jbc.M109.094235

Casey, 2009, Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer, Breast Cancer Res. Treat., 114, 47, 10.1007/s10549-008-9982-8

Richardson, 2006, X chromosomal abnormalities in basal-like human breast cancer, Cancer Cell., 9, 121, 10.1016/j.ccr.2006.01.013

Carrick, 2006, Genetic variations in ZFP36 and their possible relationship to autoimmune diseases, J. Autoimmun., 26, 182, 10.1016/j.jaut.2006.01.004

Comeron, 2004, Selective and mutational patterns associated with gene expression in humans: influences on synonymous composition and intron presence, Genetics, 167, 1293, 10.1534/genetics.104.026351

Nackley, 2006, Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure, Science, 314, 1930, 10.1126/science.1131262

Duan, 2003, Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor, Hum. Mol. Genet., 12, 205, 10.1093/hmg/ddg055

Kimchi-Sarfaty, 2007, A silent polymorphism in the MDR1 gene changes substrate specificity, Science, 315, 525, 10.1126/science.1135308

Raponi, 2010, Alternative splicing: good and bad effects of translationally silent substitutions, FEBS J., 277, 836, 10.1111/j.1742-4658.2009.07519.x

Czech, 2010, Silent mutations in sight: co-variations in tRNA abundance as a key to unravel consequences of silent mutations, Mol. Biosyst., 6, 1767, 10.1039/c004796c

Tsai, 2008, Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima, J. Mol. Biol., 383, 281, 10.1016/j.jmb.2008.08.012

Tuller, 2010, Translation efficiency is determined by both codon bias and folding energy, Proc. Natl Acad. Sci. USA, 107, 3645, 10.1073/pnas.0909910107

Bornes, 2004, Control of the vascular endothelial growth factor internal ribosome entry site (IRES) activity and translation initiation by alternatively spliced coding sequences, J. Biol. Chem., 279, 18717, 10.1074/jbc.M308410200

Schmittgen, 2008, Analyzing real-time PCR data by the comparative C(T) method, Nat. Protoc., 3, 1101, 10.1038/nprot.2008.73

Eckert, 2004, Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis, Cancer Res., 64, 4585, 10.1158/0008-5472.CAN-04-0396

Bastide, 2008, An upstream open reading frame within an IRES controls expression of a specific VEGF-A isoform, Nucleic Acids Res., 36, 2434, 10.1093/nar/gkn093

Beauclair, 2007, Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity, Ann. Oncol., 18, 1335, 10.1093/annonc/mdm181